Lecture image placeholder

Premium content

Access to this content requires a subscription. You must be a premium user to view this content.

Monthly subscription - $9.99Pay per view - $4.99Access through your institutionLogin with Underline account
Need help?
Contact us
Lecture placeholder background
VIDEO DOI: https://doi.org/10.48448/x0b3-v795

technical paper

ENDO 2022

July 11, 2022

Atlanta, United States

Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia

Please log in to leave a comment

Downloads

Transcript English (automatic)

Next from ENDO 2022

A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature
technical paper

A Prospective Clinical Trial of Vosoritide in Selected Genetic Causes of Short Stature

ENDO 2022

Andrew Dauber

11 July 2022

Similar lecture

Differential Interactions of Vitamin D Binding Protein and Vitamin D Receptor in Different Ethnic Groups with Aggressive Thyroid Cancer
technical paper

Differential Interactions of Vitamin D Binding Protein and Vitamin D Receptor in Different Ethnic Groups with Aggressive Thyroid Cancer

ENDO 2022

Salma Khan

11 July 2022

Stay up to date with the latest Underline news!

Select topic of interest (you can select more than one)

PRESENTATIONS

  • All Lectures
  • For Librarians
  • Resource Center
  • Free Trial
Underline Science, Inc.
1216 Broadway, 2nd Floor, New York, NY 10001, USA

© 2023 Underline - All rights reserved